OverviewSuggest Edit

Equillium is a biotechnology company developing products for autoimmune and inflammatory disorders and immuno-inflammation. The Company’s first product candidate, EQ001, is a clinical-stage monoclonal antibody that targets the immune receptor CD6. It plays a central role in effector T cell activity, which drives a number of immuno-inflammatory diseases such as graft versus host disease, asthma, uveitis, colitis, lupus and multiple sclerosis.

TypePublic
Founded2017
HQSan Diego, US
Websiteequilliumbio.com

Latest Updates

Employees (est.) (Jun 2019)16(+7%)
Share Price (Jun 2020)$3.2 (-4%)

Key People/Management at Equillium

Krishna Polu

Krishna Polu

Chief Medical Officer
Jason Keyes

Jason Keyes

Chief Financial Officer
Joel Rothman

Joel Rothman

SVP of Development Operations
Daniel Bradbury

Daniel Bradbury

Executive Chairman
Stephen Connelly

Stephen Connelly

Chief Scientific Officer
Bala Manian

Bala Manian

Director
Show more

Equillium Office Locations

Equillium has an office in San Diego
San Diego, US (HQ)
2223 Avenida De La Playa #108, La Jolla
Show all (1)

Equillium Financials and Metrics

Equillium Revenue

USD

Net income (Q1, 2020)

(7.8m)

EBIT (Q1, 2020)

(7.5m)

Market capitalization (3-Jun-2020)

57.5m

Closing stock price (3-Jun-2020)

3.2

Cash (31-Mar-2020)

20.6m

EV

46.6m
Equillium's current market capitalization is $57.5 m.
Annual
USDFY, 2017FY, 2018FY, 2019

General and administrative expense

378.3k3.7m9.1m

R&D expense

1.3m4.9m17.6m

Operating expense total

1.7m8.6m26.7m

EBIT

(1.7m)(8.6m)(26.7m)
Quarterly
USDQ3, 2017Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020

General and administrative expense

33.8k1.0m2.6m2.2m2.1m2.7m

R&D expense

49.9k1.2m3.8m4.3m4.2m4.7m

Operating expense total

83.7k2.2m6.3m6.4m6.3m7.5m

Depreciation and amortization

5.0k
Annual
USDFY, 2017FY, 2018FY, 2019

Cash

7.1m28.5m13.2m

Prepaid Expenses

1.2m2.3m

Current Assets

7.1m67.1m55.4m

PP&E

2.1k63.5k93.0k
Quarterly
USDQ2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020

Cash

6.6m5.0m21.4m22.7m27.7m20.6m

Prepaid Expenses

1.0m852.0k671.0k2.1m

Current Assets

6.7m5.1m62.6m57.8m62.9m49.8m

PP&E

22.0k31.9k83.0k77.0k71.0k89.0k
Annual
USDFY, 2017FY, 2018FY, 2019

Net Income

(2.3m)(13.3m)(25.6m)

Depreciation and Amortization

122.06.1k23.0k

Accounts Payable

243.7k842.7k775.0k

Cash From Operating Activities

(662.2k)(7.5m)(22.9m)
Quarterly
USDQ3, 2017Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020

Net Income

(1.2m)(3.3m)(8.3m)(5.9m)(12.0m)(18.0m)(7.8m)

Depreciation and Amortization

1.9k3.7k5.0k11.0k17.0k8.0k

Accounts Payable

33.3k103.1k352.0k455.0k890.0k1.6m(39.0k)

Cash From Operating Activities

(267.4k)(2.1m)(3.7m)(4.5m)(9.2m)(13.9m)(6.4m)
USDY, 2020

EV/EBIT

-6.3 x

EV/CFO

-7.3 x

Financial Leverage

1.4 x
Show all financial metrics

Equillium Operating Metrics

FY, 2017

Phase II Patients Enrolled

110

Phase III Patients Enrolled

223
Show all operating metrics

Equillium Online and Social Media Presence

Embed Graph

Equillium News and Updates

Equillium Reports First Quarter 2019 Financial Results and Recent Highlights

EQUATE Phase 1b/2 trial in acute graft-versus-host disease (aGVHD) ongoing with data expected in 1Q 2020

Equillium Reports Fourth Quarter and Full-Year 2018 Financial Results and Recent Highlights

Initiated the EQUATE Phase 1b/2 trial in acute graft-versus-host disease in March 2019 Initiated the EQUATE Phase 1b/2 trial in acute graft-versus-host disease in March 2019

Equillium to Host Business Update Call on February 26

LA JOLLA, Calif., Feb. 19, 2019 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a biotechnology company developing treatments for severe immune-inflammatory disorders, will be hosting a call with shareholders and the investment community to provide a business update on Tuesday, February 26, 2019…

Equillium Reports Third Quarter 2018 Financial Results and Recent Highlights

Completes Successful Initial Public Offering Raising Gross Proceeds of Approximately $71.6 Million

Biocon second-quarter profit surges on gains from Equillium stake sale

(Reuters) - Indian biotechnology company Biocon Ltd posted an over five-fold rise in second-quarter profit on Thursday, as the company recorded a one-off gain of 1.89 billion rupees ($25.79 million).

Equillium Blogs

Equillium to Present Translational Preclinical Data Demonstrating Increased Survival and Decreased Disease Severity in Models of Graft-Versus-Host Disease Treated with Itolizumab at the Transplantation & Cellular Therapy Meetings of ASTCT & CIBMTR

Equillium to Present Translational Preclinical Data Demonstrating Increased Survival and Decreased Disease Severity in Models of Graft-Versus-Host Disease Treated with Itolizumab at the Transplantation & Cellular Therapy Meetings of ASTCT & CIBMTR Content Import Wed, 01/29/2020 - 16:07 …

Equillium & Biocon Expand Exclusive Licensing Agreement for Itolizumab to Include Australia and New Zealand

Equillium & Biocon Expand Exclusive Licensing Agreement for Itolizumab to Include Australia and New Zealand Content Import Thu, 12/12/2019 - 07:00 Equillium & Biocon Expand Exclusive Licensing Agreement for Itolizumab to Include Australia and New Zealand December 12,…

Equillium Granted U.S. FDA Fast Track Designation for Itolizumab for the Treatment of Lupus Nephritis

LA JOLLA, Calif., Dec. 09, 2019 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging deep understanding of immunobiology to develop products to treat severe autoimmune and inflammatory disorders, today announced that the U.S.

Equillium to Present Translational Data on Itolizumab for Acute Graft-Versus-Host Disease at 61st American Society of Hematology (ASH) Annual Meeting and Exposition

Equillium to Present Translational Data on Itolizumab for Acute Graft-Versus-Host Disease at 61st American Society of Hematology (ASH) Annual Meeting and Exposition Content Import Tue, 11/26/2019 - 16:07 Equillium to Present Translational Data on Itolizumab for Acute Graft-Versus-Host Dise…

Equillium Featured in Panel Discussion at Capital Markets Day for Kidney Health

Equillium Featured in Panel Discussion at Capital Markets Day for Kidney Health Content Import Fri, 11/15/2019 - 08:05 Equillium Featured in Panel Discussion at Capital Markets Day for Kidney Health November 15, 2019 This release is a backfill from a News Wire…

Equillium Announces Leadership Updates

Equillium Announces Leadership Updates Content Import Tue, 11/12/2019 - 16:07 Equillium Announces Leadership Updates November 12, 2019 This release is a backfill from a News Wire General Effective January 1, 2020 Bruce Steel will assu…
Show more

Equillium Frequently Asked Questions

  • When was Equillium founded?

    Equillium was founded in 2017.

  • Who are Equillium key executives?

    Equillium's key executives are Krishna Polu, Jason Keyes and Joel Rothman.

  • How many employees does Equillium have?

    Equillium has 16 employees.

  • Who are Equillium competitors?

    Competitors of Equillium include Cellmid, Riboxx and Tridek-One.

  • Where is Equillium headquarters?

    Equillium headquarters is located at 2223 Avenida De La Playa #108, La Jolla, San Diego.

  • Where are Equillium offices?

    Equillium has an office in San Diego.

  • How many offices does Equillium have?

    Equillium has 1 office.